PATENT CLAIM ANALYSIS

Application Number: 15904935
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "252160"]

Abstract:
The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK inhibitor and an HSP90 inhibitor to the subject.

Claim (Index 2):
The pharmaceutical composition of  claim 1 , wherein the CDK inhibitor is Kenpaullone, PKC-412, Butyrolactone I, Cdk1/5 Inhibitor, Flavopiridol (Alvocidib) (such as, Flavopiridol hydrochloride), N9-Isopropyl-olomoucine, Indirubin-3\u2032-monoxime, NU2058, Olomoucine II, 9-Cyanopaullone, 5-Iodo-Indirubin-3\u2032-monoxime, NU6102, Oxindole I, SU 9516, Roscovitine, RO-3306, 10Z-Hymenialdisine, AZD 5438, AT7519, Dinaciclib, R547, CGP 74514A, SNS-032 (BMS-387032), BMS-265246, JNJ-7706621, PHA-793887, P276-00, PHA-767491, Milciclib (PHA-848125), NU6027, LDC000067, ribociclib (Kisqali\u00ae), palbociclib (Ibrance\u00ae), or abemaciclib (Vernenio\u00ae).

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.41379
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14131183', '15115606', '15026413', '15103187', '14229221']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7698983068305694
- 35 USC 102 Novelty (BERT): 0.4958760081556673
- Combined Prediction Score: 0.7424960769630793
- Mean Citation Score: 245.182056
- Max Citation Score: 255.38828
- Similarity Product: 207.3314523113728

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test